Australia's Consumer Health Trend · May–June 2026 Issue

Consumer Health
Trend Intel

Commercial signals, shelf moves, and category momentum across Australian pharmacy and grocery — curated for brand managers, category strategists, and retail buyers.
3 May – 6 Jun 2026 20 Signal Items 7 Categories Pharmacy · Grocery Vol. 2 · Issue 3
Market Thesis

GLP-1's pharmacy halo is lifting adjacent baskets, NMN is moving from niche to shelf, and private label supplements are winning consumer trust at the grocery checkout — rewriting winter 2026's commercial playbook.

Australia's consumer health commercial landscape shifted notably in May–June 2026. Three forces converged: the GLP-1 boom at Chemist Warehouse drove a +40% unit uplift in associated supplement baskets; NMN longevity products secured 8 SKUs at CWH with a formal exclusivity structure; and Coles' Ultralife private label won dual Product of the Year awards — confirming that grocery-shelf supplements have crossed the consumer trust threshold. These are not isolated events. They represent a fundamental repositioning of how Australians are buying health, and which channels they trust to sell it.

+16.7%
GLP-1 Sales YTD
CWH/Sigma GLP-1 pharmacy sales to April 2026; GLP-1 consumer health basket +40% in units
8 SKUs
NMN at CWH
CWH holds formal exclusivity with CellVive through Dec 2027 across its NMN longevity range
2× POY
Coles Ultralife
Ashwagandha Tablets + Adult Hair Skin Nails Gummies both won Product of the Year 2026
Ingredient Shift

Longevity ingredients enter the mainstream pharmacy shelf

NMN has moved from specialist e-commerce to CWH's front-of-aisle supplement range. CellVive's Dec 2027 exclusivity signals that this is a structured commercial arrangement, not a ranging trial.

Channel Convergence

Grocery earns consumer trust in supplements

Coles Ultralife's double POY win — in adaptogens AND beauty gummies — closes the credibility gap between grocery and pharmacy in the supplement aisle. Private label in grocery is no longer a discount play; it is a premium signal.

Basket Expansion

GLP-1 users building multi-category supplement baskets

The +40% unit uplift in GLP-1-adjacent consumer health products at CWH confirms that weight-management pharmacy customers are cross-shopping into VMS, protein, and wellness supplements in a single visit.

Signals at a Glance
5 Movements Defining This Period
GLP-1 Pharmacy Halo CWH/Sigma GLP-1 Rx sales +16.7% YTD to April 2026; adjacent consumer health basket +40% units.
Gummy Format Explosion Sirio presented 7 TGA-compliant gummy concepts at CMA Innovation Day (21 May 2026) spanning beauty, gut, cardiovascular, and immune categories.
Priceline Retail Media Launch Zitcha-powered Sponsored Search is now live across 9.5M loyalty member network, with McPherson's as founding partner.
Winter Flu Super-K Wave A/H3N2 subclade K is circulating early; Healthylife is running 10× Rewards on immunity until 30 June, accelerating seasonal fill.
TGA Compliance Reset Permissible Indications transition closed 5 March 2026 — ARTG entries that didn't update are cancelled. Category-wide compliance risk is real.
Key Decision

Suppliers and brand owners who rode the NMN hype without formalising exclusivity, or who delayed TGA Permissible Indications updates, face ranging vulnerability now. The commercial window for winter 2026 immunity is open — but only to brands that are compliant, in-store, and already visible on retail media platforms before flu season peaks in July.

Longevity & Healthy Ageing (VMS)

Rising
Trending nowNMN longevity supplements; postbiotics emerging alongside probiotics at CWH
Consumer needsCellular energy, healthy ageing, longevity optimisation, anti-ageing from within
Ingredients / formatsNMN (nicotinamide mononucleotide); postbiotics; capsule and powder formats; premium positioning
Notable brandsCellVive (CWH exclusive to Dec 2027), Melrose FutureLab, BioHack Wanderlust; Blackmores (postbiotic supplier partner at CWH)
Pharmacy vs groceryFirmly pharmacy-led. NMN commands $60–$120 price points unsuited to grocery. Postbiotics are beginning to surface in pharmacy editorial but have not yet ranged in grocery.
Seasonality / timingNo seasonal ceiling — longevity health is year-round. CWH's exclusivity structure accelerates rate-of-sale while the category is novel.
Commercial implicationBrands without CWH exclusivity are locked out of the market's primary NMN gateway through December 2027. Competing brands must build DTC and independent pharmacy distribution now.

Cold / Flu / OTC Immunity

Rising
Trending nowFlu season activation: Super-K A/H3N2 variant, Healthylife 10× Rewards, CWH flu vaccination push, Codral/DURO-TUSS campaigns
Consumer needsFlu prevention and treatment, symptom relief, family protection, pharmacist-led vaccination
Ingredients / formatsBenzydamine (Difflam Kids), OTC analgesics/decongestants; intranasal LAIV flu vaccine (new in 2026); echinacea, zinc, vitamin C in VMS immune range
Notable brandsDifflam Kids (Sore Throat Spray, May 2026); Codral, DURO-TUSS; Herbs of Gold 40% off at Healthylife; LAIV (Seqirus Flumist, state-funded)
Pharmacy vs groceryPharmacy leads on vaccination, OTC treatment, and high-dose immune VMS. Grocery (Healthylife) activating on mid-tier immune supplements via loyalty. Coles/Woolworths carry mainstream VMS immunity.
Seasonality / timingPeak AU flu season is June–August. The Super-K variant is circulating early. Window is open now — brands not in-store by end of June miss peak demand.
Commercial implicationEarly flu season combined with a new variant creates promotional urgency. Healthylife's 10× Rewards promotion runs to 30 June and is actively pulling category spend forward.

Gut Health & Probiotics

Rising
Trending nowUltra-high CFU probiotics (100B+); postbiotic education emerging at CWH; Women's Flora variant launch
Consumer needsDigestive wellness, immune modulation via gut, women's intimate microbiome health, post-antibiotic recovery
Ingredients / formatsMulti-strain probiotics (20 strains, 100B CFU); postbiotics (heat-inactivated ferments); capsule and sachet formats
Notable brandsBioglan Platinum Probiotics 100B (CWH exclusive, Women's Flora variant); Blackmores (postbiotic Fermented Whole Food range)
Pharmacy vs groceryPharmacy leads on premium high-CFU products. Grocery carries mainstream Yakult-adjacent probiotics and lower-CFU VMS. The postbiotic segment is pharmacy-exclusive for now.
Seasonality / timingAutumn–winter is the natural gut/immune crossover moment. Post-cold/flu antibiotic use drives probiotic fill. Timing aligns perfectly with CWH's flu activation.
Commercial implicationBioglan's 100B CFU / 20-strain positioning raises the efficacy bar for the category. Competitors with lower-potency products face a clinical communication gap at the pharmacy counter.

Sports Nutrition

Rising
Trending nowFull-range pharmacy entry by Australian sports nutrition brands; protein + collagen convergence; greens + creatine cross-category bundling
Consumer needsMuscle building, recovery, active lifestyle health, performance nutrition for mainstream gym-goers
Ingredients / formatsWhey/blend proteins, collagen peptides, creatine monohydrate, magnesium, greens blends; powder format dominant
Notable brandsBSc Body Science (full range at CWH from June 2026: protein+collagen, greens+creatine, magnesium)
Pharmacy vs groceryCWH's BSc listing moves pharmacy into direct competition with supplement specialty retailers (MyProtein, Bulk Nutrients). Grocery lags significantly on sports nutrition ranging.
Seasonality / timingWinter gym season; January new-year fitness intent has matured into committed habit by June. Pharmacy sports nutrition captures the health-motivated consumer who already shops CWH for VMS.
Commercial implicationCWH's BSc exclusivity threatens independent gym supplement retailers and specialty sports nutrition stores. Watch for competitor brands seeking similar pharmacy gateway listings at Priceline or Terry White.

Beauty from Within & Hair

Rising
Trending nowHair growth supplements at pharmacy; sensitive skin/eczema pharmacy entry (BEETL); women's wellness multi-benefit stacks (EZZ MeTime)
Consumer needsHair growth and retention, skin barrier repair, cortisol/stress-related beauty concerns, nail/skin/hair stacking
Ingredients / formatsCapixyl + Caffeine + Eucalyptus Stem Cell (EZZ Hair Shampoo); Bionap (EZZ Corti-Calm); marine collagen, biotin, keratin in gummy/capsule
Notable brandsEZZ Hair Growth Shampoo (CWH, Jun 2026, $25.17, Australian-made); EZZ MeTime (Corti-Calm, Hunger Helper, Muscle Relief Magnesium, May 2026); BEETL Skincare (Priceline, 205 stores, May 2026)
Pharmacy vs groceryBeauty-from-within supplements straddle pharmacy and grocery. EZZ is firmly pharmacy-first. BEETL's Priceline entry confirms pharmacy leads on sensitive/clinical beauty positioning. Coles Ultralife's Hair Skin Nails POY confirms grocery is competitive in the entry segment.
Seasonality / timingAutumn/winter is peak hair-loss concern season. Stress-related hair shedding (telogen effluvium) is commonly reported 3 months after high-stress periods. Post-summer hair and skin care also drives early winter demand.
Commercial implicationEZZ's dual-launch strategy (haircare product + wellness range simultaneously) concentrates consumer awareness spend. BEETL's immediate 205-store Priceline listing signals strong pharmacy buyer confidence in clinical-positioned skincare for sensitive/eczema consumers.

Weight Management & GLP-1 Adjacent

Rising
Trending nowGLP-1 Rx driving consumer health basket expansion; satiety and metabolism supplements; protein-first positioning; EZZ Hunger Helper as OTC adjacent product
Consumer needsWeight management support, satiety, blood sugar balance, lean muscle retention during caloric deficit, complementary support for GLP-1 users
Ingredients / formatsProtein (whey, collagen), fibre, chromium, berberine, satiety botanicals; high-protein RTD formats gaining traction
Notable brandsEZZ Hunger Helper (OTC, May 2026, pharmacy distribution June 2026); CWH GLP-1 basket cross-sell (protein + VMS)
Pharmacy vs groceryPharmacy dominates the clinical/supportive segment. GLP-1 patients are active pharmacy shoppers. Grocery plays in meal-replacement and high-protein food formats but trails on the supplement side.
Seasonality / timingNo strong seasonality — GLP-1 prescribing is supply-constrained, not seasonal. The basket opportunity is active year-round as GLP-1 volume at CWH continues to climb.
Commercial implicationPharmacy brands that build a GLP-1 patient support stack (protein, gut support, micronutrients) and communicate it clearly to pharmacists will capture incremental basket value on every script dispensed.

Private Label & Grocery Supplements

Rising
Trending nowColes Ultralife double Product of Year 2026 win (Ashwagandha + Hair Skin Nails Gummies); Ultralife range expanding across marine collagen, CoQ10, sleep, liver support, vitamin D3+K2
Consumer needsValue-for-money supplements, mainstream adaptogens (ashwagandha), convenient gummy formats for daily wellness routines
Ingredients / formatsAshwagandha (KSM-66), biotin/collagen/zinc in gummy, CoQ10, marine collagen, sleep (magnesium/L-theanine), vitamin D3+K2; capsule and gummy dominant
Notable brandsColes Ultralife (Coles own-brand); Woolworths Macro (comparison); Aldi Specially Selected (intermittent ranging)
Pharmacy vs groceryGrocery private label is the fastest-growing segment in mainstream supplements. Pharmacy private label (CWH's own-brand range) competes on price, but grocery wins on convenience channel penetration.
Seasonality / timingGrocery supplement ranging resets often coincide with the new year and financial year. A mid-year Product of Year win reinforces ranging decisions and acts as a credentialing signal to casual consumers year-round.
Commercial implicationSupplier brands competing against Coles Ultralife must justify a $5–$12 price premium per unit. The POY win signals that retailers are embedding private label as a category anchor, not just a value alternative. Branded suppliers need stronger clinical positioning, pharmacist endorsement, or ingredients not available in private label.
Category Signal Distribution — May–June 2026 (by signal count and strength)
Source: TheAIChemist research, May 3 – June 6, 2026. Signal counts reflect unique commercial observations per category.
Need-State
Immunity & Seasonal Wellness
▲ Accelerating
Super-K A/H3N2 variant circulating early. Healthylife 10× Rewards running until 30 June. CWH flu vaccination push alongside OTC cold/flu brands. New LAIV intranasal vaccine (kids 2–17) expanding prevention options. Peak demand window is June–August.
Need-State
Longevity & Healthy Ageing
▲ Rising
NMN secured 8 CWH SKUs with formal exclusivity. CellVive + Melrose FutureLab + BioHack Wanderlust represent a maturing product tier. Postbiotics beginning to surface. This need-state is moving from early adopter to early majority at pharmacy.
Need-State
Gut Health & Microbiome
▲ Rising
Bioglan 100B CFU / 20-strain raises the potency bar. Postbiotics emerging as the next-wave category. CWH editorial introduced postbiotic consumer education. Winter flu season primes post-antibiotic probiotic fill demand from June onward.
Need-State
Weight Management & Metabolic Health
● Active
GLP-1 Rx basket +40% in units. EZZ Hunger Helper launching in pharmacy (Jun 2026). The consumer need is being served pharmaceutically, but the OTC and supplement layer is growing alongside it, not competing.
Need-State
Beauty & Hair from Within
▲ Rising
EZZ dual-launch (hair shampoo + women's wellness range). BEETL sensitive/eczema skincare in 205 Priceline stores. Coles Ultralife Hair Skin Nails Gummies wins POY. Pharmacy and grocery both now competing in this segment with differentiated positioning.
Need-State
Sleep, Stress & Mood
● Active
Magnesium glycinate powders are the fastest-growing format in this segment (Switch Nutrition, Herbs of Gold, Blackmores). EZZ Corti-Calm (Bionap ashwagandha extract) targeting cortisol-related stress. Winter seasonal stress supports ongoing demand.
Need-State
Family Self-Care
▲ Seasonal Spike
Difflam Kids Sore Throat Spray (May 2026, $14.99, benzydamine, 6+ yrs) fills a pharmacy gap for paediatric sore throat. LAIV needle-free flu vaccine now state-funded for under-5s in NSW/QLD/SA/WA. Family OTC immune kits are a natural basket-builder.
Need-State
Value & Everyday Wellness
▲ Rising
Coles Ultralife double POY win signals consumer acceptance of grocery-price supplements. Cost-of-living pressure continues to direct first-time supplement buyers to private label. Ashwagandha is the standout value entry-point for the adaptogen category.
Dimension Pharmacy (CWH · Priceline · Terry White) Grocery (Woolworths · Coles · Aldi)
Category leadership NMN, high-CFU probiotics, GLP-1-adjacent supplements, sports nutrition, premium beauty-from-within Mainstream VMS, ashwagandha, hair/skin/nails gummies, sleep supplements, entry-price vitamin C/D/multi
Private label momentum CWH own-brand active; Priceline brand active in skincare; lower intensity in VMS supplements vs grocery Coles Ultralife double POY win is a credentialing milestone. Woolworths Macro active. Aldi Specially Selected intermittent ranging.
Exclusivity & ranging CWH NMN exclusivity (CellVive to Dec 2027); BSc Body Science sports nutrition exclusive; Bioglan 100B CFU exclusive; BEETL at Priceline 205 stores Coles Ultralife product line breadth expanding (marine collagen, CoQ10, D3+K2, sleep, liver); grocery exclusivity rare in supplements
Seasonal activation CWH flu vaccination campaigns; Difflam Kids OTC launch; Codral/DURO-TUSS OTC promotions; immunity category promotions Healthylife (Woolworths) 10× Everyday Rewards on immunity until 30 June; Herbs of Gold 40% off; mainstream Coles immunity VMS
Retail media Priceline Zitcha-powered Sponsored Search live; 9.5M loyalty member targeting; McPherson's founding partner Woolworths media network (Cartology) and Coles 360 active; both have mature retail media platforms with health category inventory
Price positioning Premium to mid-tier; NMN $60–$120; sports nutrition $40–$80; probiotics $30–$60 Entry to mid-tier; Coles Ultralife ashwagandha ~$18–$22; hair gummies ~$15–$20; competing directly with branded entry-price products
Digital/loyalty Priceline Sisterhood loyalty 9.5M members; CWH digital advertising ecosystem; pharmacist-led recommendation Everyday Rewards (Woolworths); Flybuys (Coles); both driving personalised health supplement offers at scale

Pharmacy is consolidating premium supplement authority. The combination of CWH's NMN exclusivity, Bioglan's 100B probiotic exclusive, BSc sports nutrition entry, and Priceline's live retail media platform means pharmacy is pulling away from grocery on new product velocity and premium category development. Pharmacist-backed recommendation and clinical credentialing are advantages grocery cannot easily replicate.

Grocery is winning on value, format, and accessibility. Coles Ultralife's double POY win is not a fluke — it reflects a deliberate range build across 10+ supplement categories that now competes credibly on ingredient quality (KSM-66 ashwagandha, marine collagen) at price points 30–50% below branded equivalents. For cost-conscious first-time supplement buyers, grocery is the most accessible trial channel.

The strategic implication for brand owners is channel clarity. Brands trying to win in both channels simultaneously face margin compression and retailer conflict. The clearest path is category-specific positioning: own a premium clinical story at pharmacy, or own a value-at-scale story at grocery — not both. The middle ground is increasingly owned by retailer private label.

Chemist Warehouse
Exclusive-Range Strategy Deepens Across NMN, Sports Nutrition, and High-Potency Probiotics
CWH is systematically building exclusive category positions: CellVive NMN (to Dec 2027), BSc Body Science full sports range (June 2026), and Bioglan Platinum 100B CFU probiotics. This is not opportunistic ranging — it is a deliberate strategy to own premium ingredient sub-categories before competitors can range them. The GLP-1 basket expansion (+40% units YTD) adds a revenue compounding effect, as high-frequency Rx dispensing customers cross-shop supplement categories in the same visit. Combined with CWH's UK expansion (MoU with GreenLight Healthcare, Hoxton St London), the retailer is in an assertive international and domestic growth mode that supplier brands must acknowledge in their ranging strategy.
Priceline (Wesfarmers Health)
Retail Media Network Goes Live — Zitcha-Powered Sponsored Search Now Active Across 9.5M Members
Priceline launched a fully operational retail media network powered by Zitcha, with McPherson's as the founding advertising partner. Sponsored Search targeting Priceline Sisterhood's 9.5 million loyalty members is now live. This transforms Priceline from a passive ranging partner to an active media revenue business. Suppliers who invest in Priceline's retail media early will benefit from lower CPCs and share-of-voice advantages before the network matures. BEETL skincare's simultaneous 205-store national launch confirms Priceline is backing new-to-market brands with confidence — a signal of buyer appetite for fresh ranging.
Woolworths (Healthylife)
10× Everyday Rewards Immunity Activation Accelerates Winter Category Fill
Healthylife is running a 10× Everyday Rewards points promotion on immunity-positioned products until 30 June 2026, with Herbs of Gold participating at 40% off. This is a defensive play against CWH's flu vaccination and OTC cold/flu dominance — using the Woolworths loyalty ecosystem to pull pharmacy customers into the grocery health channel before peak flu season. The promotion window aligns strategically with the Super-K A/H3N2 early circulation. Suppliers with immunity-positioned products at Healthylife should be activating co-promotional spend against this window immediately.
Coles (Ultralife)
Double Product of the Year Win Signals Private Label Supplement Credentialing Milestone
Coles Ultralife won Product of the Year 2026 in two distinct supplement categories: Ashwagandha Tablets (adaptogens) and Adult Hair Skin Nails Gummies (beauty supplements). This is the strongest public credentialing signal Coles' private label supplement range has achieved. It validates Coles' long-term strategy of building a broad, quality-positioned supplement range under its own brand — one that competes not just on price but on product quality and consumer recognition. The Ultralife range now spans marine collagen, CoQ10, sleep support, liver support, vitamin D3+K2, and immunity categories. Branded supplement suppliers at Coles must build differentiation strategies that POY recognition alone cannot provide.
Sirio / Contract Manufacturing
7 TGA-Compliant Gummy Innovation Concepts Presented at CMA Innovation Day (21 May 2026)
Sirio presented seven new TGA-compliant gummy supplement concepts at the Complementary Medicines Australia Innovation Day, covering beauty, gut health, cardiovascular, metabolic, immune, eye health, and stress/sleep categories. This is a direct signal to supplement brand owners that the infrastructure for rapid gummy innovation is mature and TGA-pathway-ready. As gummy supplements are the fastest-growing dosage format in the Australian VMS market, Sirio's presentation effectively lowered the barrier to new entrant gummy launches across multiple categories simultaneously.
2026-05-03 — 2026-06-06
CWH/Sigma GLP-1 Pharmacy Sales +16.7% YTD to April 2026; Consumer Health Basket +40% Units
Weight Management & GLP-1 Adjacent Pharmacy Confirmed High Impact

CWH / Sigma Healthcare reported GLP-1 prescription sales growth of +16.7% year-to-date to April 2026. Critically, the associated consumer health basket — supplements, protein, and wellness products purchased alongside or after a GLP-1 script — grew +40% in units over the same period. This basket expansion is being driven by pharmacist recommendation, in-store merchandising, and GLP-1 patient awareness of complementary nutrition needs.

Commercial implication: Every new GLP-1 dispensing is a high-value supplement cross-sell opportunity. Pharmacy brands with protein, gut support, micronutrients, and satiety supplements should be activating co-location and pharmacist education programmes at CWH as a priority.
2026-05-03 — 2026-06-06
NMN Category at CWH: 8 SKUs, CellVive Exclusivity to December 2027
Longevity & Healthy Ageing Pharmacy Confirmed High Impact

Chemist Warehouse has built a structured NMN longevity supplement category with 8 SKUs, anchored by an exclusivity arrangement with CellVive through December 2027. Complementary brands Melrose FutureLab and BioHack Wanderlust are also ranged. The category occupies dedicated shelf space in the healthy ageing / longevity section, reflecting CWH's strategy of category-building around high-value ingredient trends before broader pharmacy adoption.

Commercial implication: Competing NMN brands are effectively locked out of Australia's largest pharmacy retailer through end of 2027. Alternative channels are independent pharmacy, DTC online, and practitioners — brands must activate these now to build awareness for the post-exclusivity period.
2026-06-01
BSc Body Science Full Sports Range Listed at Chemist Warehouse — June 2026
Sports Nutrition Pharmacy Confirmed High Impact

BSc Body Science secured a full-range listing at Chemist Warehouse from June 2026, covering protein and collagen products, a greens and creatine range, and a magnesium recovery line. The listing brings mainstream sports nutrition into the pharmacy channel at scale, directly competing with specialist supplement retailers. CWH's pharmacy footprint and its GLP-1 basket opportunity make sports nutrition cross-sell highly viable alongside weight management and recovery supplement conversations.

Commercial implication: Specialist supplement retailers (e.g., MyProtein, Bulk Nutrients, Protein Supplies Australia) face material channel disruption. CWH's pricing power and traffic volume will accelerate trial among non-gym consumers entering sports nutrition via the health channel.
2026-05-03 — 2026-06-06
Bioglan Platinum Probiotics 100B CFU / 20 Strains — CWH Exclusive with Women's Flora Variant
Gut Health & Probiotics Pharmacy Confirmed High Impact

Bioglan launched its Platinum Probiotics line at CWH — a 100 billion CFU, 20-strain probiotic in an exclusive CWH ranging arrangement, with a Women's Flora variant addressing feminine microbiome health. The 100B CFU threshold represents a significant escalation from the previous 30–50B category norm in Australia, positioning Bioglan Platinum as a clinically serious product at pharmacy counter level.

Commercial implication: Competitors with sub-50B CFU products face a consumer perception gap at CWH. The Women's Flora variant creates a distinct need-state lane (intimate microbiome health) that is underserved in Australian retail probiotics.
2026-05-03 — 2026-06-06
Coles Ultralife Wins Dual Product of the Year 2026 — Ashwagandha Tablets + Adult Hair Skin Nails Gummies
Private Label & Grocery Supplements Grocery Confirmed High Impact

Coles Ultralife won Product of the Year 2026 in two supplement categories: Ashwagandha Tablets and Adult Hair Skin Nails Gummies — making it one of the strongest private label supplement credentialing events in Australian retail history. The Ultralife range now includes marine collagen, CoQ10, sleep support, liver health, vitamin D3+K2, and immunity products, with ongoing category expansion signalled by Coles buyers.

Commercial implication: Coles Ultralife has closed the quality perception gap with mid-tier branded supplements. This is a direct threat to branded supplement suppliers at Coles who cannot justify their price premium against an award-winning private label alternative.
2026-05-21
Sirio Presents 7 TGA-Compliant Gummy Concepts at CMA Innovation Day
Gummy Format Innovation Both Confirmed High Impact

Sirio, a leading global gummy contract manufacturer, presented seven new TGA-compliant gummy formulation concepts at Complementary Medicines Australia's Innovation Day (21 May 2026), covering beauty, gut health, cardiovascular, metabolic health, immune support, eye health, and stress/sleep categories. All concepts are designed for the Australian regulatory pathway, reducing time-to-market for brands seeking to enter or expand gummy formats.

Commercial implication: The gummy format barrier to entry has dropped significantly. Brand owners can now launch TGA-pathway-ready gummies across seven category areas without proprietary formulation investment. Expect a wave of new gummy launches into CWH and grocery in H2 2026 and into 2027.
2026-05-03 — 2026-06-06
Winter Flu Super-K Wave Arrives Early — A/H3N2 Subclade K Circulating; Healthylife 10× Rewards Activation
Cold / Flu / OTC Immunity Both Confirmed High Impact

A/H3N2 subclade K (Super-K) is circulating earlier than historical norms in 2026 across eastern Australia. Healthylife responded with a 10× Everyday Rewards points promotion on immunity products until 30 June, with Herbs of Gold at 40% off. CWH is running flu vaccination campaigns and Codral/DURO-TUSS OTC campaigns are active. Peak flu season typically hits July–August, meaning the early activation window is advantageous for brands already in-store.

Commercial implication: Immunity brands in-store and on promotion before late June will capture early-wave consumers. Brands reliant on peak-season promotional placements booked for July may miss the 2026 early build.
2026-05-01
Difflam Kids Sore Throat Spray Launches — Benzydamine, 6+ Years, $14.99, CWH / Priceline / Coles / TWC
Cold / Flu / OTC Immunity Both Confirmed Medium Impact

Reckitt launched Difflam Kids Sore Throat Spray in May 2026 — a benzydamine-based topical sore throat treatment formulated for children 6 years and over, priced at $14.99 and ranging across CWH, Priceline, Coles, and Terry White Chemists. The launch fills a pharmacy gap for paediatric topical sore throat relief ahead of peak flu season. Benzydamine provides both analgesic and anti-inflammatory action directly at the throat mucosa.

Commercial implication: Difflam Kids targets a genuine paediatric OTC gap — most sore throat topicals are not indicated for under-12s. The broad multi-channel listing (pharmacy + grocery) maximises seasonal trial during peak illness months. Parent-targeted communication is the key media lever.
2026-05-01
EZZ MeTime Women's Wellness Range Launches — Corti-Calm, Hunger Helper, Muscle Relief Magnesium
Beauty from Within & Hair · Women's Wellness Both Confirmed Medium Impact

EZZ launched its MeTime women's wellness range in May 2026 — three products: Corti-Calm (featuring Bionap botanical extract for cortisol modulation), Hunger Helper (satiety support, OTC positioning), and Muscle Relief Magnesium (recovery). Pharmacy distribution is scheduled from June 2026. The range targets stress-driven beauty and body concerns, linking cortisol with weight, skin, and hair outcomes — a narrative strongly active in social and search health media.

Commercial implication: EZZ's multi-product women's wellness approach creates stacking purchase opportunities at the pharmacy counter. The cortisol-beauty link is a high-engagement consumer narrative that pharmacists can support in consultation.
2026-06-02
EZZ Hair Growth Shampoo Listed at CWH — $25.17, Capixyl + Caffeine + Eucalyptus Stem Cell, Australian-Made
Beauty from Within & Hair Pharmacy Confirmed Medium Impact

EZZ's Hair Growth Shampoo launched at CWH on 2 June 2026 at $25.17, featuring Capixyl (a patented hair growth peptide), caffeine, and Eucalyptus Stem Cell. The product is Australian-made, a provenance claim that resonates with pharmacy consumers. Capixyl has published clinical efficacy data, giving the product a pharmacist-recommendation pathway beyond typical shampoo conversations.

Commercial implication: EZZ's simultaneous launch of a clinically-backed haircare product and women's wellness supplement range creates a coherent anti-hair loss portfolio narrative. Pharmacist education on Capixyl efficacy will differentiate from mass-market hair loss shampoos.
2026-05-11
BEETL Skincare Lists at Priceline — 205 Stores, NZ Clinical Brand, Sensitive / Eczema / Baby Positioning
Beauty from Within & Hair · Derma Skincare Pharmacy Confirmed Medium Impact

BEETL Skincare, a New Zealand clinical derma brand, listed at Priceline across 205 stores from 11 May 2026. The range targets sensitive skin, eczema-prone skin, and baby skincare — a segment where consumers strongly prefer pharmacist recommendation. BEETL's NZ clinical credentials and formulation philosophy align with Priceline's growing focus on clinical skin health beyond traditional beauty.

Commercial implication: BEETL's immediate 205-store listing confirms Priceline's buyer appetite for international clinical skincare with a credible derma story. NZ and AU brands in the clinical derma space should view this as a market signal that the Priceline buyer is actively looking for differentiated ranging in sensitive/eczema skincare.
2026-05-04
Postbiotics Emerging at CWH — Consumer Education Push Ahead of Category Launch
Gut Health & Probiotics Pharmacy Emerging Medium Impact

CWH published consumer education content on 4 May 2026 introducing postbiotics ("You've Heard of Probiotics, But Have You Heard of Postbiotics?"), with Blackmores as the supplier partner. Postbiotics — the bioactive compounds produced by probiotic bacteria — represent the next evolution of the gut health category, offering greater stability and shelf-life vs live probiotic cultures. CWH's editorial push typically precedes formal product ranging by 4–8 weeks.

Commercial implication: Postbiotic product launches at CWH are likely imminent. Brands with postbiotic formulations should be in active ranging conversations now. Consumer education content is the typical leading indicator of a formal CWH category activation.
2026-05-03 — 2026-06-06
Priceline Retail Media Network Live — Zitcha Sponsored Search, 9.5M Members, McPherson's as Founding Partner
Retail Media & Channel Strategy Pharmacy Confirmed Medium Impact

Priceline has launched a full retail media network powered by Zitcha, with Sponsored Search now live against its 9.5 million Priceline Sisterhood loyalty members. McPherson's is the founding advertising partner — one of Australia's leading health, beauty and wellness distribution companies. The network enables targeted health and beauty advertising at the point of purchase, with loyalty-data audience segmentation.

Commercial implication: Priceline's retail media network adds a new paid performance channel for health and beauty brands at one of Australia's most influential pharmacy retail touchpoints. Early adopter CPCs will be lower than mature network pricing — first-mover brands gain algorithmic and awareness advantages.
2026-05-03 — 2026-06-30
Healthylife 10× Everyday Rewards on Immunity — Herbs of Gold 40% Off — Until 30 June
Cold / Flu / OTC Immunity Grocery Confirmed Medium Impact

Healthylife (Woolworths' online health platform) is running a 10× Everyday Rewards points promotion on immunity-category products until 30 June 2026. Herbs of Gold is featured at 40% off. The promotion targets the pre-peak flu season window, using loyalty incentives to drive trial and basket fill before peak pharmacy flu season competition intensifies in July.

Commercial implication: Immunity supplement brands listed at Healthylife should activate co-promotional support now. The 10× Rewards mechanic has high redemption rates within the Woolworths loyalty ecosystem — brands that participate will see material volume lifts during the promotion window.
2026-05-03 — 2026-06-06
Intranasal LAIV Flu Vaccine Now Available in Australia — Needle-Free, Children 2–17, State-Funded in 4 States
Cold / Flu / OTC Immunity Pharmacy Confirmed Medium Impact

Australia introduced the intranasal Live Attenuated Influenza Vaccine (LAIV) in 2026 for children aged 2–17 years — the first needle-free flu vaccine option available domestically. NSW, QLD, SA, and WA are providing state-funded LAIV for children under 5 years. The needle-free format significantly reduces the hesitancy barrier for paediatric flu vaccination and is expected to increase overall childhood flu vaccination rates through pharmacy and GP channels.

Commercial implication: Higher paediatric flu vaccination uptake will create uplift in family immunity supplement co-purchases at pharmacy (probiotics, vitamin C, zinc, family multivitamins). Pharmacies offering LAIV should cross-merchandise family VMS immunity products at the vaccination point.
2026-03-05
TGA Permissible Indications Transition Closed — Non-Updated ARTG Entries Cancelled
Regulatory Both Confirmed High Impact

The TGA's Permissible Indications transition for listed complementary medicines closed on 5 March 2026. Listed medicine sponsors who failed to update their ARTG entries to the new permissible indications framework have had those entries cancelled. This represents a significant regulatory compliance event — any product currently on shelf that was not updated is now technically unlawful to supply. Category-wide non-compliance risk remains elevated as enforcement catches up.

Commercial implication: Brands must audit their full ARTG portfolio immediately. Cancelled entries mean the product cannot be legally marketed or supplied in Australia. Retailers may receive delistings or compliance notices. This is the highest-risk regulatory event for the complementary medicines category in 2026.
2026-05-03 — 2026-06-06
TGA Vitamin D Bone Strength: 4 Products Removed for Insufficient Evidence
Regulatory Both Confirmed Medium Impact

The TGA removed four listed complementary medicine products from the ARTG following a post-market review of Vitamin D bone strength claims. The removals were linked to insufficient evidence supporting specific bone health claim combinations. This follows TGA's ongoing use of post-market surveillance to enforce evidence standards for listed medicine health claims.

Commercial implication: Any brand making bone health + Vitamin D claim combinations should conduct an evidence review against current TGA standards. The specific claims and product categories involved should be reviewed by legal/regulatory affairs before the next ranging period.
2026-05-03 — 2026-06-06
Magnesium Glycinate Sleep/Stress Segment — Powder Format Fastest Growing; Switch Nutrition, Herbs of Gold, Blackmores
Sleep, Stress & Mood Both Emerging Medium Impact

The magnesium glycinate segment within the broader magnesium category is growing at a faster rate than the overall category, with powder formats — dissolvable, flavoured sleep-and-stress blends — driving volume. Switch Nutrition, Herbs of Gold, and Blackmores are all active in this format. The powder format aligns with social media rituals ("night drink" or "evening wind-down" trends) and commands a price premium over traditional tablet magnesium.

Commercial implication: Brands in the magnesium category that have not yet launched a powder/dissolvable format risk ceding the highest-growth format segment to competitors. Flavour and ritual positioning (rather than clinical claim alone) is the key differentiation lever in this format.
2026-05-03 — 2026-06-06
Ashwagandha Enters Mainstream Grocery — Coles Ultralife POY Win Validates Category Crossover
Private Label & Grocery Supplements Grocery Confirmed High Impact

Coles Ultralife Ashwagandha Tablets' Product of the Year 2026 win formally validates ashwagandha's crossover from pharmacy adaptogen to mainstream grocery supplement. The recognition demonstrates that grocery shoppers are actively selecting and repurchasing ashwagandha — a market signal that the category has passed the novelty phase and entered everyday wellness purchasing behaviour at the grocery checkout.

Commercial implication: Branded ashwagandha suppliers at Coles (and other grocery retailers) must now justify their premium over an award-winning private label with ingredient standardisation (KSM-66 vs non-standardised), dose transparency, or clinical evidence communication.
2026-05-03 — 2026-06-06
CWH UK Expansion — MoU with GreenLight Healthcare, First Store Hoxton St London, Phase 1 Up to 5 Stores
Retailer Strategy — Global Pharmacy Confirmed Medium Impact

Chemist Warehouse signed a Memorandum of Understanding with GreenLight Healthcare to open its first UK stores, with Hoxton Street, London as the flagship location and a Phase 1 target of up to 5 stores. The CWH UK model will replicate the high-volume, low-price pharmacy model that disrupted Australian retail pharmacy. UK market entry positions CWH as an international retail pharmacy brand and signals ambition well beyond the Australian domestic market.

Commercial implication: Australian supplement and health brands already working with CWH should explore whether their products can be included in CWH UK's initial ranging. Early-stage international distribution via CWH UK could be commercially material for brands with appropriate margin structures and UK regulatory clearance.
TGA — Regulatory
Permissible Indications Transition: Non-Updated Products Now Cancelled
The TGA Permissible Indications transition closed 5 March 2026. Sponsors who did not update their ARTG entries have had those entries cancelled. Products currently on shelf with cancelled ARTG entries cannot lawfully be supplied. All brands must urgently audit their ARTG portfolio and confirm all listed medicines are current. This is the highest compliance priority in 2026 for complementary medicine suppliers.
Critical Risk
TGA — Post-Market Review
Vitamin D Bone Strength Claims: 4 Products Removed
Four listed complementary medicines were removed from the ARTG following TGA post-market review of Vitamin D bone strength claim combinations. Brands making bone health + Vitamin D cross-category claims should review their evidence base against current TGA permissible indications before any upcoming ARTG renewal or promotional campaign.
High Risk
TGA / Ad Standards — Seasonal Claims
Flu Season Immunity Claims: Peak Risk Window for Non-Compliant Advertising
Winter flu season (June–August) generates the highest density of immunity supplement advertising in Australia. This is also the period with the most Ad Standards and TGA Advertising Complaints. Claims including "prevent colds and flu," "kill viruses," "clinical strength," and implied pharmaceutical efficacy for listed medicines are high-risk. All flu season campaigns should be reviewed against TGA Advertising Guidelines and Ad Standards Code before launch.
High Risk
TGA — GLP-1 Adjacent Claims
OTC Satiety and Weight Management Claims: Elevated Scrutiny
As GLP-1 adjacency becomes a commercial marketing angle for OTC supplements (e.g., EZZ Hunger Helper, satiety blends), TGA scrutiny of weight management claims for listed medicines is intensifying. Claims implying GLP-1-like mechanisms, pharmaceutical weight loss outcomes, or clinical equivalence to prescription medicines in OTC supplement marketing are not permissible under current TGA listed medicine standards.
Medium Risk
ACCC — Consumer Law
Private Label "Clinical" and "Pharmacist Recommended" Positioning
As grocery private label supplements (Coles Ultralife, Woolworths Macro) expand and win award recognition, some products are beginning to adopt pharmacy-style clinical language in packaging and marketing. ACCC consumer law requires that "pharmacist recommended," "clinically tested," and "scientifically proven" claims are substantiated. Private label brands should ensure their claims are fully supported before using clinical positioning language that may not be accurate for a non-clinical retail environment.
Medium Risk
TGA — Postbiotic Claims
Postbiotic Definition and Health Claims: Regulatory Ambiguity
The term "postbiotic" is not formally defined under the TGA's complementary medicine framework. As brands begin using this term in consumer marketing (CWH blog content, Blackmores editorial), regulatory guidance on permissible postbiotic claims has not yet been issued. Brands launching postbiotic products should seek TGA pre-market advice on permitted labelling claims to avoid post-launch compliance issues.
Medium Risk
01

GLP-1 Patient Supplement Stack — Build the Pharmacist-Recommended Bundle at CWH

The +40% GLP-1 adjacent supplement basket at CWH is not being served by a coordinated brand narrative. The first brand to develop and communicate a pharmacist-validated "GLP-1 support stack" — protein, gut support, magnesium, B-vitamins, and satiety — will capture the basket compounding effect. This is an immediate commercial opportunity at the world's highest-volume pharmacy retailer.

Why now: CWH/Sigma reported the +40% basket uplift to April 2026. The opportunity is active and growing with each new GLP-1 script dispensed. Pharmacy channel with GLP-1 inventory concentration makes CWH the natural launch partner. Autumn/winter is peak new-patient GLP-1 initiation season.
02

Winter Immunity Bundle — Early Season Capture Before Peak July Competition

The Super-K A/H3N2 variant is circulating earlier than historical norms. Brands with immunity supplements — zinc, elderberry, echinacea, vitamin C, and high-CFU probiotics — that are in-store and on promotion by end of June will capture early-wave demand before peak competition in July. Healthylife's 10× Rewards mechanic provides an additional loyalty-driven demand pull through the end of June.

Why now: Early flu season confirmed by public health surveillance. Healthylife 10× Rewards activation runs until 30 June. Intranasal LAIV increasing family pharmacy visit frequency creates cross-sell moments. Brands waiting for a July promotional slot will miss the early build.
03

Gummy Format Expansion Across Multiple Categories — Sirio's TGA-Ready Pipeline

Sirio's CMA Innovation Day presentation of 7 TGA-compliant gummy concepts across beauty, gut, cardiovascular, metabolic, immune, eye health, and sleep categories means the formulation pathway is already open. Brand owners who move quickly into Sirio's pipeline across 2–3 of these categories can launch premium, TGA-registered gummy products in H2 2026 — ahead of the expected wave of competitor launches in 2027.

Why now: Sirio presented the concepts publicly on 21 May 2026 — the pipeline is live. Gummies are the fastest-growing dosage format in AU consumer health. Consumer preference for gummy format is consistent across age groups and category segments. First-mover advantage in TGA-registered premium gummies vs unregistered alternatives is substantial.
04

Postbiotic First-Mover in AU Pharmacy — Ahead of the CWH Ranging Activation

CWH published consumer postbiotic education content on 4 May 2026 — an editorial signal that typically precedes formal category ranging by 4–8 weeks. Brands with TGA-registered postbiotic formulations should be in active ranging conversations with CWH buyers now. The first brand to secure pharmacy shelf space in the postbiotic segment will define the category and set pricing architecture before competition enters.

Why now: CWH editorial introduction of postbiotics on 4 May 2026 is the strongest ranging lead indicator available. Blackmores' supplier partnership in the content signals their intent — but the shelf space is not yet locked. Brands with ready formulations have a narrow window to engage buyers before the category is committed.
05

Priceline Retail Media Early Adopter — Sponsor Search Before CPCs Mature

Priceline's Zitcha-powered retail media network is newly live with Sponsored Search across 9.5 million loyalty members. Cost-per-click rates are lowest at network launch and rise as more advertisers enter. Health, beauty, and personal care brands listed at Priceline should activate Sponsored Search campaigns immediately to establish share of voice and algorithmic position before the network matures and CPCs increase materially.

Why now: Priceline retail media launched in Q2 2026 — McPherson's has already entered as founding partner. Winter flu season creates peak search intent for immunity, cold/flu, and health products. Early-network CPCs historically 40–60% lower than mature network rates. Flu season timing aligns perfectly with activation window.
Regulatory
TGA Permissible Indications Enforcement — Cancelled ARTG Entries Still on Shelf
The March 2026 transition deadline has passed and enforcement is active. Any brand with products on shelf under a cancelled ARTG entry faces potential TGA enforcement action, retailer delisting, and reputational damage. The risk is particularly acute for smaller brands with large portfolios who may have missed individual ARTG updates. Retailers may begin receiving formal notices — brands should communicate proactively with retail buyers about compliance status.
Category Saturation
NMN Exclusivity Cliff — Post-December 2027 Category Overcrowding
CWH's CellVive NMN exclusivity runs to December 2027. When it expires, the NMN category will likely see rapid entry by 5–10 competing brands competing for the same CWH shelf space previously locked. Brands building NMN awareness and distribution through alternative channels now will be better positioned for the post-exclusivity market; brands waiting for CWH access will face a crowded category with established leaders already embedded.
Private Label Pressure
Grocery Private Label Supplement Credentialing — Branded Premium Compression
Coles Ultralife's double POY win signals that private label supplement quality perception is reaching parity with mid-tier branded products. Brands with a $5–$12 premium over Ultralife in categories like ashwagandha, hair/skin/nails, and collagen must build clinical differentiation, practitioner endorsement, or ingredient provenance (KSM-66, Verisol, marine collagen source) claims that private label cannot easily replicate. Brands that do not act will face ranging rationalisation at Coles and Woolworths in 2027 resets.
GLP-1 Adjacent Claims
OTC Products Implying GLP-1 Mechanism Risk TGA Action
The commercial opportunity of GLP-1 adjacency is real, but brands marketing OTC supplements with implied pharmaceutical weight-loss mechanisms are at elevated regulatory risk. "GLP-1 support," "natural Ozempic," or satiety claims that imply prescription medicine equivalence are not permissible for listed medicines. As TGA increases post-market advertising monitoring, brands in this space should expect targeted review of any GLP-1-adjacent marketing language.
Flu Season Uncertainty
Super-K Variant Intensity vs Consumer Stock-Building — Inventory Risk
Early circulation of Super-K A/H3N2 may prompt earlier and more intense seasonal stocking by both retailers and consumers — creating potential for inventory gaps at peak (July–August) if initial build orders are not scaled to meet accelerated demand. Conversely, if the variant proves less severe than forecast, brands that over-committed on promotional inventory face post-season clearance pressure. Scenario-based ordering and promotional commitment visibility is essential before July.
Channel Conflict
Sports Nutrition Pharmacy Entry — Disruption Risk for Specialty Supplement Retailers
BSc Body Science's full CWH listing places mainstream sports nutrition into pharmacy for the first time at scale. Independent supplement specialty retailers and online-only sports nutrition brands face a pricing and accessibility disadvantage once CWH drives trial at its ~600 domestic stores. Brands that supply both channels must manage pricing and product differentiation carefully to avoid channel conflict and retailer margin friction.
Trend AU Visibility Entry Channel Barriers Timing
CWH UK Expansion (GreenLight Healthcare MoU) Confirmed AU Active — MoU signed, Hoxton St London as first store, Phase 1 up to 5 stores International pharmacy retail — AU brand export opportunity via CWH UK UK MHRA regulatory clearance for listed medicines; UK consumer pricing expectations; logistics; brand awareness build from zero Immediate — CWH UK store opening imminent
Ozempic Face / GLP-1 Body Composition Aesthetics (US) Watch Not yet an AU retail trend but US social and clinical media is driving consumer awareness Premium pharmacy, derma clinic, medical aesthetics TGA does not permit GLP-1 adjacency in OTC claims; consumer-level awareness of GLP-1 body/face effects is lower in AU than US; cultural framing differences 12–18 months to AU retail relevance; monitor US beauty media for leading indicators
Postbiotics — US / European Category Build (Pendulum, WholoBiome) Early AU CWH blog content (4 May 2026) is the first formal AU consumer education signal; no confirmed retail ranging yet Premium pharmacy; Healthylife online; practitioner channel TGA has no formal postbiotic definition; "postbiotic" label claims need TGA pre-market advice; Australian consumer education still early-stage 4–8 weeks to first AU pharmacy ranging if brands are ready; 12 months to mainstream grocery
Taurine Longevity Supplement Wave (US — Science 2023 landmark study) Early AU No AU retail movement yet; small DTC/practitioner visibility; US taurine supplement sales +180% post-study Online DTC, independent pharmacy; ultimately mainstream pharmacy if clinical narrative builds Taurine is not an unusual ingredient — low TGA barrier — but no clinical positioning at AU retail yet; low consumer awareness; competing with established magnesium and B-vitamin supplement spend 6–12 months if US momentum continues; watch for brand launches at naturalproductsexpo.com or CHFA
Creatine Beyond Sports — Female Wellness and Cognitive Health Positioning (US / UK) Early AU Signal BSc Body Science's greens+creatine CWH listing bridges sports and mainstream wellness; no female-specific creatine products at AU retail yet Pharmacy sports nutrition; mainstream pharmacy VMS; online Creatine's gender-neutral and cognitive positioning narrative is not yet established at AU retail; female consumer adoption requires targeted communication strategy beyond gym-specific channels 6–12 months for female wellness creatine products to emerge at AU pharmacy; watch UK sports nutrition brands entering AU
Functional Beauty Ingestibles — UK / US Prestige Channel (MAELYS, HUM Nutrition, Gold Collagen) Early AU Prestige beauty supplements very limited in AU retail; BEETL's Priceline listing is closest signal in clinical skin positioning Premium pharmacy, Mecca, department store beauty, Priceline premium tier AU consumers less familiar with prestige-positioned ingestible beauty; higher price points ($60–$150 per month) than current AU pharmacy collagen/biotin entry level; regulatory labelling for cosmetic vs therapeutic claims 12–24 months to AU retail mainstream; monitor Mecca and Sephora AU for early listings
For Brand Owners
Channel clarity and compliance urgency are your two immediate priorities
  • Audit your full ARTG portfolio for TGA Permissible Indications compliance now — cancelled entries create ranging vulnerability and regulatory exposure.
  • Decide whether your core market is pharmacy (clinical, premium, exclusive) or grocery (value, accessible, mainstream) — competing in both without differentiation risks margin compression and channel conflict.
  • If you have a GLP-1 adjacent supplement, build a pharmacist-validated product narrative that avoids impermissible mechanism claims but captures the basket opportunity at CWH.
  • If you have a postbiotic or NMN formulation, engage CWH buyers immediately — the ranging windows for these categories are open and time-sensitive.
For Pharmacy Retailers
GLP-1 basket activation and winter flu season are your dual commercial levers for H1 2026
  • Develop a GLP-1 patient supplement recommendation protocol for pharmacists — the +40% basket uplift is not self-sustaining without structured recommendation.
  • Ensure your immunity and OTC cold/flu ranges are fully stocked and promoted before end of June — the Super-K early season creates demand pull that pre-July promotional plans may miss.
  • Activate Priceline retail media Sponsored Search early — first-mover CPCs are lowest now and flu season creates peak search intent for health products.
  • Build a winter family self-care kit narrative around LAIV paediatric vaccination cross-sell with family probiotics and vitamin C.
For Grocery Retailers
Private label credibility has arrived — now build the premium bridge before pharmacy takes the initiative
  • Coles Ultralife's double POY win is a ranging and ranging-reset asset — use it in buyer negotiations with branded supplement suppliers to reset margin expectations.
  • Expand Ultralife into postbiotics, magnesium glycinate powders, and NMN once CWH exclusivity expires — these are the next mainstream supplement categories.
  • Healthylife's 10× Rewards immunity mechanic should be replicated for the winter gut health and sleep supplement categories — the loyalty data exists to target the right shopper.
  • Watch BSc Body Science CWH listing carefully — if sports nutrition proves successful at pharmacy, Woolworths and Coles will need a competing sports nutrition ranging strategy by mid-2027.
For Insights & Strategy Teams
Three structural shifts are underway that will reshape category definitions and channel hierarchies
  • Track GLP-1 pharmacy basket data quarterly — the composition of the GLP-1 adjacent basket (which supplement categories are most commonly cross-purchased) will define new product development priorities for 2027 and beyond.
  • Monitor postbiotic consumer awareness via search and social data — when awareness crosses the 15% threshold in Australia, mainstream pharmacy ranging will accelerate rapidly.
  • Develop a private label supplement competitive index — tracking Coles Ultralife and Woolworths Macro ingredient quality, pricing, and ranging expansion is now as strategically important as tracking major branded competitors.
  • Model the NMN post-exclusivity scenario (post-Dec 2027) for category sizing, pricing architecture, and brand entry/exit scenarios.
For Executives & Investors
Three structural trends are compounding: GLP-1 pharmacy halo, private label supplement credentialing, and NMN longevity category formation
  • CWH's GLP-1 Rx volume (+16.7% YTD) combined with +40% adjacent supplement basket growth represents a material revenue compounding effect that is likely to accelerate as GLP-1 supply constraints ease.
  • Coles Ultralife's credentialing milestone is a leading indicator of grocery becoming a structurally larger share of the AU supplement market — this changes the competitive landscape and margin outlook for branded supplement suppliers across the next 3–5 years.
  • NMN longevity supplement category in AU is pre-commercialisation — the post-Dec 2027 open market will be the key investment window for brands seeking NMN category positions at scale.
  • CWH UK expansion (GreenLight Healthcare MoU) introduces an international revenue dimension to an otherwise domestic Australian retail pharmacy investment thesis.

Ride the GLP-1 Halo — But With Compliant, Pharmacist-Led Narratives

The GLP-1 basket opportunity at CWH is the single highest-value commercial activation available to supplement brands in Australian pharmacy right now. But the mechanism is pharmacist recommendation — not consumer marketing that implies OTC GLP-1 equivalence. The winning strategy is a clearly defined "GLP-1 patient support" product set (protein, gut health, electrolytes, B-complex, satiety fibre) with a pharmacist education programme that positions these supplements as clinically appropriate co-interventions — not pharmaceutical alternatives. Brands that activate this with CWH pharmacists before competitors arrive will own the cross-sell narrative.

Own a Category-Defining Ingredient Before Exclusivity Matures

CWH's strategy of building exclusive brand relationships in high-value ingredient categories (NMN, BSc sports, Bioglan 100B probiotics) creates first-mover monopoly positions at scale. The lesson for brands is clear: bring a category-defining ingredient narrative to CWH with exclusivity terms before a competitor does. Postbiotics, taurine longevity, magnesium glycinate powder formats, and creatine female wellness are the categories where exclusive category arrangements are still possible in 2026. Brands with ready formulations in these areas should be in CWH buyer conversations now.

Build Differentiation That Private Label Cannot Buy

Coles Ultralife's double POY win closes the perception gap on ingredient quality for mainstream supplement categories. The competitive moats that private label genuinely cannot replicate are: clinical evidence (published RCTs, efficacy data), branded ingredient provenance (KSM-66, Verisol, Longvida curcumin), pharmacist endorsement, therapeutic goods advertising approval, and specialist practitioner recommendation. Brands competing in ashwagandha, hair/skin/nails, collagen, or sleep categories without at least two of these differentiators are at serious ranging risk as Coles and Woolworths extend Ultralife and Macro into more supplement categories.

Activate Winter Flu Season Now — Early Wave Demands Pre-July Visibility

Super-K's early circulation in 2026 has moved the commercial flu season window forward by 3–4 weeks. Brands with immunity supplements — echinacea, elderberry, zinc, vitamin C, high-CFU probiotics, and OTC cold/flu products — that are in-store, on promotion, and on Priceline's Sponsored Search before the end of June will capture the early wave. Brands relying on July promotional placements will face peak competition with less upside available. The single highest-ROI action for immunity brands right now is activating Healthylife's 10× Rewards programme, booking Priceline Sponsored Search, and confirming CWH promotional activity before 30 June.

Treat Gummy Format as a Strategic Platform, Not a Tactic

Sirio's 7 TGA-compliant gummy concepts across 7 categories signal that gummy format innovation is now infrastructure, not novelty. For brands that have not launched a gummy SKU, the strategic question is no longer whether gummies are appropriate — they are — but which categories to enter first and how to differentiate on taste, dose, and ingredient provenance within a format that is becoming commoditised. The brands that will win in gummies are not those who launch fastest but those who build the best consumer ritual experience (flavour, texture, packaging) and the most credible clinical story. This is a 24-month window before the gummy category becomes fully crowded at every retailer.